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Abstract
Background: There is a high prevalence of cognitive impairment in dialysis patients. The prevalence of cognitive
impairment after kidney transplantation is unknown.
Methods: Study Design: Cross-sectional study. Setting and Participants: Single center study of prevalent kidney transplant
recipients from a transplant clinic in a large academic center. Intervention: Assessment of cognition using the Montreal
Cognitive Assessment (MoCA). Demographic and clinical variables associated with cognitive impairment were also
examined. Outcomes and Measurements: a) Prevalence of cognitive impairment defined by a MoCA score of
<26. b) Multivariable linear and logistic regression to examine the association of demographic and clinical
factors with cognitive impairment.
Results: Data from 226 patients were analyzed. Mean (SD) age was 54 (13.4) years, 73% were white, 60%
were male, 37% had diabetes, 58% had an education level of college or above, and the mean (SD) time
since kidney transplant was 3.4 (4.1) years. The prevalence of cognitive impairment was 58.0%. Multivariable
linear regression demonstrated that older age, male gender and absence of diabetes were associated with
lower MoCA scores (p < 0.01 for all). Estimated glomerular filtration rate (eGFR) was not associated with level
of cognition. The logistic regression analysis confirmed the association of older age with cognitive impairment.
Conclusion: Cognitive impairment is common in prevalent kidney transplant recipients, at a younger age compared to
general population, and is associated with certain demographic variables, but not level of eGFR.
Keywords: Cognitive impairment, Kidney transplantation, MoCA
Background
Cognitive impairment is prevalent in as many as 50 to
87% of dialysis patients [1, 2] and influences quality of
life, employment rates, treatment adherence, hospital
admissions, health care costs, morbidity and mortality
[3–5]. Kidney transplant recipients, like patients on dia-
lysis, have several risk factors for cognitive impairment
such as comorbid illness, depression, and lower level of
physical activity [6, 7]. Kidney transplantation offers
quality of life and survival advantages over dialysis [8].
Cognitive impairment in kidney transplant recipients is
associated with increased mortality [9, 10]. Some studies
suggest cognitive impairment, especially in domains of
verbal learning, memory and executive functioning in
kidney transplant recipients when compared to healthy
controls [11]. However, the actual prevalence of cogni-
tive impairment in transplant recipients is unknown.
The knowledge of the prevalence of cognitive impair-
ment is an important first step for designing future
studies to assess the clinical impact of cognitive impair-
ment and develop management strategies. Some studies
indicate that cognition improves with kidney transplant-
ation [12–16]. These studies, however, do not assess the
prevalence of cognitive impairment in kidney transplant
recipients as they were designed specifically to evaluate
the impact of transplantation on cognition. The aim of
this study is to evaluate the prevalence of cognitive im-
pairment in kidney transplant recipients by screening
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eligible kidney transplant recipients. In addition, we evalu-
ated the factors associated with cognitive impairment.
Methods
Study population
Adult kidney transplant recipients followed at the
University of Kansas Kidney Transplant Clinic were in-
cluded if they were i) English speaking; ii) without a his-
tory of acute stroke, concussion or traumatic brain
injury within 2 months of testing and iii) with no acute
illness at the time of participation. Patients were ex-
cluded if they i) had hearing or visual impairment; ii)
were unable to read, write, speak or understand English;
iii) had uncontrolled psychosis or seizure disorder; iv)
were currently using antipsychotics or anti-epileptics v)
received dual organ transplantation or vi) had a known
history of cognitive impairment or dementia. Cognition
was assessed during the clinic visit for post-transplant
care. Eligible patients who attended the transplant clinic
between May 2015 and June 2016 were approached. To
minimize the acute effect of high dose steroids, surgery,
and possible post-operative complications, cognitive as-
sessments were performed only after the patient was at
least 1 month post-transplant. As part of a standardized
protocol, all patients were maintained on a mycopheno-
lic acid compound and a calcineurin inhibitor with or
without prednisone.
Outcome variable
Cognition was assessed with the Montreal Cognitive
Assessment (MoCA), a brief cognitive screening instru-
ment (Additional file 1) [17]. The MoCA is a validated,
clinic-based tool that samples from various domains of
cognition and is sensitive in detecting mild cognitive
impairment in several diseases, including Alzheimer’s
disease and vascular dementia [18, 19]. We chose MoCA
over the more commonly used mini-mental state exam
(MMSE) for detecting cognitive impairment, as MoCA
has more focus on executive function, a domain more
commonly affected in kidney disease [20]. Moreover,
MoCA has been successfully used in kidney disease, with
a good correlation with detailed neuropsychological
testing and better results than MMSE [21]. MoCA con-
sists of a single page test with a maximum score of 30.
The MoCA takes less than 10 min to complete and
assesses seven domains of cognition: visuospatial/execu-
tive, naming, memory (delayed recall), attention, lan-
guage, abstraction and orientation. The original English
version 7.1 was used (http://www.mocatest.org/paper-
tests/moca-test-full/). Based on published validation data
on patients from a memory clinic, we defined cognitive
impairment as MoCA score of less than 26 [17]. The
MoCA was administered by medical assistants who
underwent an hour of training that included detailed
review of the online instructions along with practice
sessions on mock patients. These medical assistants per-
formed the test on the transplant recipients in a private
examination room during the patients routine clinic visit
to the transplant center.
Exposure variables
Demographic and clinical variables that can potentially
influence cognition such as age, gender, ethnicity, level
of education, body mass index (BMI), blood pressure,
history of smoking, diabetes, coronary artery disease,
atrial fibrillation, transient ischemic attack (TIA) or
stroke, cause for ESRD, serum hemoglobin, estimated
glomerular filtration rate (eGFR), time on dialysis prior
to transplant, and time after transplant were included in
the analysis. Body mass index (BMI) and blood pressure
were collected by medical assistants immediately before
administration of MoCA. Demographic information and
medical history were obtained through review of the pa-
tient’s electronic medical record. Diabetes was defined as
current or past use of oral hypoglycemic agents or insu-
lin. Coronary artery disease was defined as history of
myocardial infarction, angina pectoris, angioplasty or
coronary artery bypass surgery. Hypertension was de-
fined by past or current use of antihypertensive agents.
However, hypertension was not included in the final ana-
lysis as all patients were on one or more antihypertensive
agent at some point in time. The eGFR calculated by the
Modification of Diet in Renal Disease equation closest to
the day of MOCA assessment (the same day in most
cases) was collected.
The data collection was initiated as a quality improve-
ment project and was approved by the Institutional Review
Board. Data were collected on paper forms and managed
in standard case report forms in REDCap (Research
Electronic Data Capture) a web-based, electronic data cap-
ture tool hosted on a secure, password protected, HIPAA
compliant server [22].
Statistical analysis
We compared baseline covariate values between patients
with and without cognitive impairment using the t test
for continuous variables (or rank sum test when t test
assumptions where violated as indicated by residual ana-
lysis) and the Pearson’s chi square test for categorical
variables (or Fisher’s exact test when expected cell
counts were insufficient for Pearson’s chi square test).
To ensure accuracy of data collection (MoCA scores as
well as data collected from patients medical records),
two authors reexamined all the data entered for 50 ran-
dom patients. We calculated the mean and the standard
deviation for continuous variables, and the frequencies
and the proportions for categorical variables. We further
analyzed the prevalence in patients categorized by
Gupta et al. BMC Nephrology  (2017) 18:158 Page 2 of 8
five-year age groups. With the MoCA score being a
continuous variable, we performed a multivariable lin-
ear regression analysis to study the association of
these variables with cognitive performance. In model
1 of the multivariable regression analysis, we included
all variables of interest that can affect cognition (age,
gender, race, level of education, history of diabetes,
coronary artery disease, smoking, stroke, and atrial
fibrillation, BMI, serum hemoglobin, estimated glom-
erular filtration rate, systolic and diastolic blood pres-
sure, time of dialysis, time since kidney transplant,
and end stage renal disease secondary to diabetes).
We used the adjusted R-square to determine model 2,
in which we included selected variables from model 1
on the basis of their predictive relevance. The ad-
justed R-square criterion assesses the improvement in
the amount of variation described relative to the number
of parameters in the model. Residual analyses were con-
ducted to assess the normality and constant variance as-
sumptions of the multivariable linear regression models.
We also assessed the adjusted associations of the variables
selected for Model 2 with cognitive impairment defined as
a MoCA score < 26. All tests were two-tailed. For all
analyses, P < 0.05 was considered statistically significant.
All analyses were performed using SAS version 9.4 (SAS
Institute Inc., Cary, NC, 2002–2012).
Results
Patient characteristics
A total of 297 patients were approached for the MoCA
test. Out of these, 22 patients were excluded from the
analysis due to known history of mental retardation
(five), stroke causing known cognitive deficits (two),
hearing impairment (three), visual impairment (five), or
inability to speak fluent English (seven). Eight patients
refused to complete the assessment and two started the
assessment, but did not complete it. After excluding the
above 32 patients, 265 kidney transplant recipients com-
pleted the MoCA. Of these, 226 (>85%) had complete
data and were included in the analyses. Examination of
data for 50 random patients (total of 1250 data points)
by two authors revealed high accuracy of data with a
total of seven errors. As shown in Table 1, the mean age
of the participants was 54.0 (SD 13.4) years. Participants
were predominantly white, male, and with an education
level of college or above. About half of the study partici-
pants were obese defined by a BMI ≥ 30 (50.9%). The
mean eGFR was 52 ± 21 ml/min/1.73 m2. The average
time on dialysis prior to transplant was 2.3 years (SD
2.1) and the average time since transplant was 3.4 years
(SD 4.1). Only 3% of the participants had a history of
TIA or stroke and 21% had a history of coronary artery
disease.
Cognitive assessment
Fifty eight percent reached criteria for cognitive impair-
ment. Table 1 compares the patients with and without
cognitive impairment. The mean age of patients with
cognitive impairment was higher than patients without
cognitive impairment (p ≤ 0.01), and a lower proportion
of female patients had cognitive impairment (p = 0.02).
Race, level of education, BMI, systolic and diastolic
blood pressure, eGFR, time since transplantation, time
on dialysis prior to transplantation, and a history of
smoking, coronary artery disease, atrial fibrillation, dia-
betes, or the cause of ESRD were not different among
those with and without cognitive impairment.
In the bivariate analysis, higher MOCA scores were
associated with lower age (p < 0.001), female gender
(p < 0.001), lower serum hemoglobin levels (p = 0.015),
and higher level of education (p = 0.003). There was no
association of the MOCA score with race, BMI, blood
pressure, eGFR, time since kidney transplantation, time
on dialysis prior to transplantation, history of smoking,
stroke, diabetes, coronary artery disease, atrial fibrilla-
tion, and ESRD secondary to diabetes. Multivariable
linear regression demonstrated that higher MOCA score
was associated with younger age, female gender, a higher
level of education, and diabetic status (Table 2). Model 1
includes all variables of interest entered in the analysis.
Model 2 includes variables selected on the basis of their
predictive relevance based on the adjusted R-square
(Additional file 2).
When considering the dichotomous outcome of cogni-
tive impairment older age was associated with higher
risk (Table 3). With the higher prevalence of cognitive
impairment in older transplant recipients, we also ana-
lyzed the prevalence of cognitive impairment by five-
year age groups (Fig. 1). These results demonstrate an
increased prevalence of cognitive impairment with older
age, but notably also a high prevalence of cognitive im-
pairment even in individuals less than 50 years old.
Discussion
We examined the prevalence and covariates of cognitive
impairment in a cohort of kidney transplant recipients.
A majority of the transplant recipients with mean age of
54 years had cognitive impairment with the overall
prevalence being more than two times the prevalence in
those 65 years or older in the general population [23, 24].
Lower MoCA scores were associated with older age, male
gender, and a lower level of education. These data under-
score that cognitive impairment is common in kidney
transplant recipients and additional studies are needed so
as to understand the pathophysiology and impact of cog-
nitive impairment in these individuals.
Several studies have shown that cognitive impairment
is common in dialysis patients [1, 2]. In this study we
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show a high prevalence of cognitive impairment in kid-
ney transplant recipients. We noted a higher prevalence
of cognitive impairment with higher age. This trend is
similar to that seen in the general population but occurs
at a much younger age in kidney transplant recipients.
For example, compared to a prevalence of 16–20% in
adults 65 years or older in the general population [23, 24],
we noted that a majority of the transplant recipients had
cognitive impairment even at age of 40 years or less.
Not much is known about cognition and brain changes
after kidney transplantation. Although cognition improves
after kidney transplantation [12–16], our data suggest that
that cognitive impairment in dialysis patients may not be
entirely reversible. Several potential mechanisms may ex-
plain the cognitive impairment observed in kidney trans-
plant recipients. Despite improvement in kidney function
after transplantation, prolonged exposure to comorbid
medical conditions including metabolic and vascular
changes that are associated with kidney disease may result
in non-reversible cerebrovascular disease that persists after
successful transplantation. Alteration of the microbiome,
immunomodulation, and neurotoxicity from medications
such as calcineurin inhibitors or steroids may also contrib-
ute to cognitive impairment in transplant recipients.
We did not detect a relationship between cognition and
eGFR. This is in contrast to pre-dialysis CKD where the
severity of cognitive impairment is correlated with severity
of renal dysfunction [4, 25]. This implies that the etiology
of cognitive impairment in dialysis and kidney transplant
recipients cannot be entirely attributed to a lower level of
GFR but that other factors mentioned above contribute.
Patients on dialysis are indeed exposed to metabolic and
hemodynamic alterations that might contribute to cogni-
tive impairment. Although there is an association with
eGFR in pre-transplant CKD, cognitive impairment in this
population may as well be due to several other factors
such as vascular alterations, chronic inflammation and co-
morbid conditions such as diabetes and hypertension. It is
Table 1 Demographic and clinical characteristics of study participants
Patient characteristics All MoCA <26 MoCA ≥26 p-value
N = 226 N = 131 N = 95
Age (years) 54 (13.4) 56.7 (13.5) 51.3 (12.8) <0.01
Gender 0.02
Female 89 (39.4) 43 (32.8) 46 (48.4)
Race 0.57
Caucasian 165 (73.0) 93 (71.0) 72 (75.8)
African American 43 (19.0) 28 (21.4) 15 (15.8)
Other race 18 (8.0) 10 (7.6) 8 (8.4)
Education level 0.08
≥ College 130 (57.5) 69 (52.7) 61 (64.2)
BMI 0.65
≥ 30 (kg/m2) 115 (50.9) 65 (50) 50 (52.6)
Blood Pressure
Systolic (mmHg) 139 (18) 140 (19) 137 (17) 0.29
Diastolic (mmHg) 73 (12) 72 (12) 74 (13) 0.09
Serum hemoglobin (g/dl) 12.5 (2) 12.7 (2.1) 12.1 (1.9) 0.03
eGFR (ml/min/1.73 m2) 52 (21) 53 (21) 51 (22) 0.38
Time since KT (years) 3.4 (4.1) 3.3 (3.6) 3.6 (4.8) 0.72a
Time on dialysis (years) 2.3 (2.1) 2.3 (1.93) 2.2 (2.3) 0.16a
H/o smoking 95 (42.0) 57 (43.5) 38 (40.0) 0.60
H/o TIA/stroke 7 (3.1) 4 (3.1) 3 (3.2) >0.99a
H/o diabetes 84 (37.2) 49 (37.4) 35 (36.8) 0.93
H/o CAD 42 (21.2) 26 (19.9) 16 (16.8) 0.57
H/o Atrial Fibrillation 25 (11.1) 16 (12.2) 9 (9.5) 0.52
ESRD secondary to diabetes 57 (25.2) 34 (26.0) 23 (24.2) 0.77
Continuous variables = Mean (Standard deviation), Categorical variables = N (%)
The p-values indicate the comparison between MoCA <26 and MoCA ≥26.
BMI body mass index, eGFR estimated glomerular filtration rate, KT kidney transplant, H/o history of, TIA transient ischemic attack, CAD coronary artery disease
aNonparametric test
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also likely that cognitive impairment in pre-dialysis CKD
takes several years to develop while level of eGFR in the
transplant recipient only reflects a short period of the in-
dividual’s life-time exposure to cognitive risk.
Diabetes and hypertension have been associated with
cognitive impairment and white matter hyperintensities
in the brain [26, 27]. We did not note a relationship
between the presence of diabetes and cognitive impair-
ment. This may be due to selection bias in that the
healthier diabetic patients receive kidney transplants.
Despite the similarity between the general population
and the transplant recipients in age related cognitive
decline, cognitive impairment in transplant recipients
may be different from Alzheimer’s disease, the most
common cause of cognitive impairment in the general
population. For example, unlike Alzheimer’s disease
[28], women performed better in the cognitive assess-
ments than men. In addition, as alluded to above, the
pathophysiology of cognitive impairment in kidney
disease, and by extrapolation, in kidney transplantation
Table 2 Association of demographic and clinical variables with the level of cognition
Model 1
Exposure variable B Coefficient 95% Confidence interval p-value
Age (/10 years) −0.659 −1.04 to −0.28 <0.001
Female 1.321 0.41 to 2.23 0.01
African Americana −1.189 −2.31 to −0.05 0.04
Other racea −0.122 −1.71 to 1.47 0.88
College education or above 0.826 −0.04 to 1.70 0.06
H/o diabetes 1.594 0.35 to 2.83 0.01
H/o CAD −0.158 −1.33 to 1.01 0.79
H/o smoking −0.573 −1.44 to 0.30 0.20
H/o TIA/stroke 0.381 −2.07 to 2.83 0.76
H/o A.fib 0.787 −0.65 to 2.22 0.28
BMI (≥30 kg/m2) 0.343 −0.52 to 1.20 0.43
Serum hemoglobin (per g/dl) −0.137 −0.38 to 0.11 0.27
eGFR (per ml/min/1.73 m2) −0.005 −0.03 to 0.02 0.62
SBP (per mm Hg) −0.011 −0.04 to 0.02 0.44
DBP (per mm Hg) 0.042 0.001 to 0.08 0.05
Time on dialysis (per year) −0.104 −0.31 to 0.11 0.33
Time since KT (per year) 0.005 −0.11 to 0.12 0.93
ESRD secondary to diabetesb 0.027 −1.33 to 1.38 0.97
Model 2
Exposure Variable B Coefficient 95% Confidence interval p-value
Age (/10 years) −0.669 −1.00 to −0.34 <0.001
Female 1.363 0.50 to 2.23 0.002
College education or above 0.922 0.09 to 1.76 0.03
H/o diabetes 1.455 0.56 to 2.35 0.002
H/o smoking −0.491 −1.34 to 0.36 0.25
H/o A. fib −0.759 −0.58 to 2.10 0.27
Serum hemoglobin (per g/dl) −0.120 −0.33 to 0.09 0.27
DBP (per mm Hg) 0.026 −0.01 to 0.06 0.15
Time on dialysis (per year) −0.000 −0.35 to 0.04 0.12
Model 1 includes all variables of interest entered in the multivariable analysis. All variables are adjusted for the other variables. Models 2 includes variables
selected on the basis of their predictive relevance using adjusted R-square criterion
H/o history of, ESRD end stage renal disease, TIA transient ischemic attack, BMI body mass index, eGFR estimated glomerular filtration rate, SBP systolic blood
pressure, DBP diastolic blood pressure, KT kidney transplant
areference group: Caucasian race. breference group: other causes of ESRD
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recipients, more likely mimics vascular dementia rather
than Alzheimer’s disease [20].
Our findings are clinically relevant. Cognitive impair-
ment may have profound effects on outcomes of kidney
transplantation [9, 10]. The care of transplant patients is
a complex combination of polypharmacy, medication
and dietary adherence, as well multiple outpatient clinic
visits and tests. Medical adherence is affected by impair-
ment in cognition and lack of adherence is a major cause
for rejection and graft loss [29, 30]. Although mild cog-
nitive impairment may not interfere notably with activ-
ities of daily living or be clinically evident, identifying
these patients is important as cognitive impairment is a
precursor to dementia with 5 to 20% of patients progres-
sing to clinical dementia annually [31].
This study has some limitations. The cross sectional
design precludes conclusions regarding cause and effect
and does not provide information on whether cognition
is stable, improving or deteriorating. Furthermore, it does
not allow comparison of current level of cognition with
that pre-transplant, or the association of current level of
eGFR with decline in cognition in follow up. Although the
prevalence of cognitive impairment was high, this may in
fact be an underestimate as we excluded patients with
known history of dementia. Depression can affect cogni-
tive performance but was not assessed in this study. We
excluded patients who did not speak English, which may
affect generalizability. The clinical data were obtained
from chart review which has its inherent limitations. We
ensured accuracy of data collection by random sampling
of 20% of the data points by two authors with 0.5% errors.
In addition we used a structured case report form to ab-
stract data. In this study we used MOCA to assess cogni-
tion. Although appropriate for this initial study, a
screening tool such as MoCA may lack the specificity that
can be achieved with more rigorous testing with detailed
neurophysiological tests. However, for clinical practice, a
simple tool such as MOCA is more practical. Further-
more, it is validated for use in outpatient clinics and can
readily be applied to clinical practice in transplant clinics.
Conclusions
The prevalence of cognitive impairment in kidney trans-
plant recipients is high. In contrast to the general popu-
lation even younger transplant recipients have a high
prevalence of cognitive impairment. This information
should be taken into consideration during patient
Fig. 1 Boxplot of MoCA scores by age range






Age (per 10 year increase) 1.33 1.06 to 1.69 0.02
Female 0.57 0.32 to 1.03 0.06
College education or above 0.73 0.41 to 1.30 0.28
H/o diabetes 0.75 0.40 to 1.39 0.37
H/o smoking 1.01 0.56 to 1.82 0.98
H/o A. fib 0.88 0.34 to 2.27 0.79
Serum hemoglobin
(per g/dl)
1.11 0.96 to 1.28 0.59
DBP (per mm Hg) 0.98 0.96 to 1.01 0.21
Time on dialysis (per year) 1.04 0.91 to 1.19 0.59
aAssociation of clinical variables with a MOCA score < 26 using
logistic regression
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education and monitoring of medical adherence. Further
research is needed to understand the pathophysiology
and consequences of cognitive impairment in transplant
recipients. Strategies to help kidney transplant recipients
cope with cognitive deficits should be developed.
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